Breaking News Instant updates and real-time market news.

RAD

Rite Aid

$8.25

-0.07 (-0.84%)

, MS

Morgan Stanley

$42.62

-0.5 (-1.16%)

07:30
12/29/16
12/29
07:30
12/29/16
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Wednesday in Rite Aid (RAD), Morgan Stanley (MS), Blackstone (BX), Mondelez (MDLZ), Zynga (ZNGA), Accelerate Diagnostics (AXDX), and Select Comfort (SCSS).

RAD

Rite Aid

$8.25

-0.07 (-0.84%)

MS

Morgan Stanley

$42.62

-0.5 (-1.16%)

BX

Blackstone

$27.33

-0.41 (-1.48%)

MDLZ

Mondelez

$44.72

-0.32 (-0.71%)

ZNGA

Zynga

$2.58

-0.01 (-0.39%)

AXDX

Accelerate Diagnostics

$21.70

-0.1 (-0.46%)

SCSS

Select Comfort

$22.87

-0.75 (-3.18%)

  • 09

    Jan

RAD Rite Aid
$8.25

-0.07 (-0.84%)

11/15/16
LEER
11/15/16
NO CHANGE
Target $85
LEER
Outperform
CVS Health price target lowered to $85 from $105 at Leerink
Leerink analyst David Larsen lowered his price target for CVS Health (CVS) to $85 from $105 as he is incrementally more cautious on the company. Conversely, the analyst is incrementally more positive on Walgreens Boots Alliance (WBA) and believes its deal with Rite Aid (RAD) deal is more likely to go through with Trump as President. Nonetheless, Larsen believes that 2017 is largely a re-set year for CVS Health, and expects the business to return to more robust growth in 2018 and beyond. He reiterates an Outperform rating on CVS Health's shares.
11/09/16
DBAB
11/09/16
NO CHANGE
Target $88
DBAB
Buy
Deutsche still expects Walgreens, Rite Aid deal to close
After speaking to private equity executives, Deutsche Bank analyst George Hill continues to expect Walgreens Boots Alliance's acquisition of Rite Aid (RAD) to be completed. The analyst says the conversations support his belief that most of the divested stores will go to strategic buyers, which he thinks is the FTC preference. Hill has a Buy rating on Walgreens with an $88 price target.
11/08/16
LEER
11/08/16
NO CHANGE
Target $90
LEER
Outperform
Walgreens Boots Alliance price target lowered to $90 from $95 at Leerink
Leerink analyst David Larsen lowered his price target for Walgreens Boots Alliance (WBA) to $90 from $95, noting that he is negatively surprised that Rite Aid (RAD) is expected to add just 5c-12c to 2017 EPS, and also somewhat concerned that 2017 is expected to be a back-half loaded year. Furthermore, the analyst is slightly more cautious on Rite Aid deal's odds, but sees about 65% chance of it closing. Larsen reiterates an Outperform rating on Walgreens Boots Alliance's shares.
12/20/16
EVER
12/20/16
NO CHANGE
EVER
Cardinal Health likely to benefit from Fred's asset acquisition, says Evercore ISI
Evercore ISI analyst Ross Muken said Cardinal Health (CAH) is likely to benefit from Fred's (FRED) acquisition of 865 stores from Walgreens Boots (WAG)/Rite Aid (RAD) as it is Fred's current distributor.
MS Morgan Stanley
$42.62

-0.5 (-1.16%)

12/21/16
ATLE
12/21/16
UPGRADE
ATLE
Neutral
Morgan Stanley upgraded to Neutral from Underweight at Atlantic Equities
12/12/16
OPCO
12/12/16
NO CHANGE
OPCO
Outperform
Opco says 'let the bet ride' on bank stocks, ups price targets
Oppenheimer analyst Chris Kotowski says that while "one cannot remain as bullish on the group as when the stocks were cheap," investors should "let the bet ride" on bank stocks. The analyst maintains a "somewhat overweight stance" on the space, but points out the shares are getting more fully valued. Kotowski's favorite names remain Bank of America (BAC), Citi (C), CIT Group (CIT) and Goldman Sachs (GS). He raised his price target for Bank of America to $25 from $19, for Citi to $72 from $65 and for Goldman to $252 from $228.
12/06/16
UBSW
12/06/16
NO CHANGE
Target $48
UBSW
Buy
Morgan Stanley valuation driven by improving investor sentiment, says UBS
UBS analyst Brennan Hawken met with Morgan Stanley management, who revealed they have an alternative plan to deal with the DOL fiduciary rule delay. The firm said they intend to push forward with a flat revenue sharing program, which will apply to both transactional and fee-based assets, resulting in greater resiliency of the revenues and modest tailwinds. Hawken believes the potential for improving investor risk appetite should drive a higher valuation. Hawken reiterated his Buy rating and $48 price target on Morgan Stanley shares.
12/21/16
12/21/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Sunoco (SUN) upgraded to Outperform from Neutral at Credit Suisse with analyst John Edwards saying valuation is "underappreciated" and said a dividend cut is unlikely given options available for Sunoco and Energy Transfer Equity (ETE) to execute before reducing payouts. 2. BP (BP) and Statoil (STO) were upgraded to Buy from Neutral at UBS. 3. Citi (C) and Bank of America (BAC) were upgraded to Overweight from Neutral at Atlantic Equities while Morgan Stanley (MS) was upgraded to Neutral from Underweight. 4. Air Products (APD) upgraded to Buy from Neutral at Monness Crespi with the firm saying it thinks that Air Products will benefit from consolidation in the industry. It says that Air Products' balance sheet will enable it to "easily bid on and win new projects" and exploit divestitures in the sector. 5. Monster Beverage (MNST) upgraded to Buy from Hold at Jefferies with analyst Kevin Grundy calling the stock his top large cap growth pick in Consumer Products. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BX Blackstone
$27.33

-0.41 (-1.48%)

03/11/16
DBAB
03/11/16
DOWNGRADE
Target $28
DBAB
Hold
Blackstone downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Brian Bedell downgraded Blackstone (BX) to Hold saying Alternative Asset Mangers will underperform over the next year amid volatile markets. The analyst lowered his price target for the shares to $28 from $30 and views Oaktree Capital (OAK) as the best positioned in the space.
03/08/16
03/08/16
NO CHANGE

Deutsche views ending of SunEdison, Vivint deal as potential positive
Deutsche Bank analyst Vishal Shah believes the termination of SunEdison's (SUNE) agreement to acquire Vivint Solar (VSLR) is a potential longer-term positive for SunEdison and TerraForm Power (TERP). The failure may also turn out to be a positive for Vivint in the long run, Shah tells investors in a research note. Investor focus will now shift from near-term liquidity and balance sheet stress for both TerraForm and SunEdison to potential legal ramifications from Vivint and Blackstone (BX), the analyst contends. He believes, however, that the legal impact may not be that significant considering the audit committee investigation and resulting lack of financing availability.
12/16/16
BOFA
12/16/16
UPGRADE
Target $34
BOFA
Buy
Blackstone upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Michael Carrier upgraded Blackstone to Buy and raised its price target to $34 from $29. The analyst said valuation has come inline with the sector and expects distribution growth of 40% in 2017. Further, Carrier expects Blackstone to be a beneficiary of tax reform and an improving outlook in the U.S.
10/26/16
10/26/16
DOWNGRADE
Target $43

Market Perform
TeamHealth downgraded to Market Perform at Leerink
As previously reported, Leerink analyst Ana Gupte downgraded TeamHealth (TMH) to Market Perform from Outperform after the recent rally on the reported talks of a potential sale to Blackstone (BX) or Bain, while raising her price target on the shares to $43 from $40 on deal probability as she sees it as more likely than 50%.
MDLZ Mondelez
$44.72

-0.32 (-0.71%)

12/15/16
JPMS
12/15/16
NO CHANGE
JPMS
JPMorgan weighs in on Swiss-based Kraft for Mondelez story
Is the Swiss-based magazine Bilanz's article that Kraft Heinz (KHC) is looking to buy Mondelez (MDLZ) legitimate? "Frankly, we do not know," JPMorgan analyst Ken Goldman tells investors in a research note. The analyst until yesterday had never heard of Bilanz. Goldman points out Bloomberg last night reported that Kraft Heinz is not currently in talks to acquire Mondelez, according to people familiar with the matter. Nonetheless, Goldman provided a hypothetical Kraft/Mondelez accretion model for investors. Assuming a 25% takeout premium on Mondelez's closing price of $42.83, the analyst estimates 25% deal accretion for Kraft. In pre-market trading, Mondelez is up $2.07, or 5%, to $44.90 while Kraft Heinz is up 2% to $85.75.
11/10/16
11/10/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BHP Billiton (BHP) initiated with a Hold at HSBC. 2. Mondelez (MDLZ) reinstated with a Hold at Deutsche Bank. 3. Yum China (YUMC) initiated with an Outperform at Oppenheimer. 4. Arch Coal (ARCH) initiated with a Buy at Seaport Global. 5. Zions Bancorp (ZIOP) coverage assumed with an Outperform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/10/16
DBAB
11/10/16
INITIATION
Target $46
DBAB
Hold
Mondelez reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Mario Contreras reinstated Mondelez with a Hold rating and $46 price target. The analyst sees "relatively limited upside" to the current valuation.
09/23/16
JPMS
09/23/16
NO CHANGE
JPMS
Neutral
JPMorgan says Mondelez speculation misguided, not pursuing Hershey again
JPMorgan analyst Ken Goldman noted that strength in Hershey (HSY) shares this morning was being attributed to speculation that Mondelez (MDLZ) might be back in talks to buy the company. However, after speaking with Mondelez, the analyst said it is clear that the company's stance is unchanged and there have been no new deal talks, nor does he think there will be any. Goldman keeps a Neutral rating on Hershey shares, which have given up their early gains and turned slightly negative for the session.
ZNGA Zynga
$2.58

-0.01 (-0.39%)

12/23/16
12/23/16
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst upgrades, downgrades and initiations with this list compiled by The Fly: 1. Brean Capital analyst Alan Gould downgraded Time Warner (TWX) to Hold from Buy, saying the arbitrage discount to the AT&T (T) offer has shrunk to 12%, down from the high-teens, and Time Warner shares now trade above his fundamental value estimate in the low $90's. 2. Argus downgraded Sun Life Financial (SLF) to Hold from Buy, with analyst Jacob Kilstein citing valuation and what he sees as "weakness in the core Canadian business, lower margins, the negative impact of a strengthening Canadian dollar," along with the company's suspension of share repurchases. 3. FedEx (FDX) initiated with a Buy at Aegis. The firm also initiated shipping peer UPS (UPS) with a Hold rating. 4. Video game retailer GameStop (GME) initiated with a Buy at Mizuho, which also started coverage of video game makers Zynga (ZNGA) and Glu Mobile (GLUU) with ratings of Buy and Neutral, respectively. 5. Skechers (SKX) upgraded to Buy from Neutral at Monness Crespi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/23/16
MZHO
12/23/16
INITIATION
Target $3.5
MZHO
Buy
Zynga initiated with a Buy at Mizuho
Mizuho analyst San Phan initiated Zynga with a Buy and a $3.50price target.
12/22/16
MZHO
12/22/16
INITIATION
Target $3.5
MZHO
Buy
Zynga initiated with a Buy at Mizuho
Mizuho initiated Zynga with a Buy rating and $3.50 price target.
11/03/16
BARD
11/03/16
NO CHANGE
Target $3
BARD
Neutral
Zynga turnaround continues, says Baird
Baird analyst Colin Sebastian noted Zynga reported better than expected Q3 results. The analyst said its performance was driven by improving monetization coupled with strength in games. Sebastian said Q3 trends were solid but Q4 looks to be soft due to a decrease in advertising bookings and minimal impact from its Dawn of the Titans game. Sebastian maintained his Neutral rating and $3 price target on Zynga shares.
AXDX Accelerate Diagnostics
$21.70

-0.1 (-0.46%)

04/11/16
PIPR
04/11/16
NO CHANGE
Target $25
PIPR
Overweight
Piper still expects FDA approval for Accelerate Diagnostics in Q3
After Accelerate Diagnostics updated its investor deck with preliminary data from its FDA clinical trial, Piper Jaffray analyst William Quirk says he continues to expect FDA approval in Q3. The company announced "generally positive" preliminary FDA clinical trial results with AST data in line with the preclinical trial, Quirk tells investors in a research note. Accelerate's ID sensitivity of 94.6%, below the 95% endpoint and 96.6% from the preclinical trial, is unlikely to impact FDA approval given the "strong" AST results and faster turnaround time versus current systems, the analyst contends. He reiterates an Overweight rating on Accelerate Diagnostics with a $25 price target.
03/24/16
03/24/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Accelerate Diagnostics (AXDX) initiated with an Overweight at JPMorgan by analyst Tycho Peterson, who said the company is well positioned to execute a successful commercial launch of the Accelerate ID/AST System and rapidly grow its install base. 2. Envestnet (ENV) initiated with a Buy at Jefferies with analyst Surinder Thind saying he expects continued market share gains for the company and views its Yodlee acquisition as transformational. 3. Pure Storage (PSTG) initiated with an Outperform at William Blair by analyst Jason Ader, who sees an attractive risk/reward equation relative to the company's growth profile. 4. PayPal (PYPL) initiated with a Neutral at Sterne Agee CRT with analyst Moshe Katri citing rich valuation and long-term potential risks to its dominant position in eCommerce. 5. Wells Fargo (WFC) initiated with a Sell at UBS by analyst Brennan Hawken, who believes risks to Wells' revenue growth and credit performance are not reflected in the current valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/24/16
JPMS
03/24/16
INITIATION
Target $17
JPMS
Overweight
Accelerate Diagnostics initiated with an Overweight at JPMorgan
JPMorgan analyst Tycho Peterson started Accelerate Diagnostics with an Overweight rating and $17 price target. The company is well positioned to execute a successful commercial launch of the Accelerate ID/AST System and rapidly grow its install base, Peterson tells investors in a research note.
05/26/16
PIPR
05/26/16
NO CHANGE
PIPR
Piper sees limited impact from new European device tax rules
Piper Jaffray analyst William Quirk points out that the European Union announced it will issue new rules for medical devices and in vitro diagnostics in the near-to-mid term. The EU is looking to strengthen rules for clearing devices/tests for the market and increase existing device/test surveillance, Quirk tells investors in a research note. He believes the new rules should not inhibit well validated tests/devices from coming to market. As such, Quirk expects little impact to Piper's in vitro diagnostic coverage universe, namely Accelerate Diagnostics (AXDX), Becton Dickinson (BDX), Cepheid (CPHD), Hologic (HOLX), Quidel (QDEL) and Meridian Bioscience (VIVO).
SCSS Select Comfort
$22.87

-0.75 (-3.18%)

12/06/16
12/06/16
DOWNGRADE
Target $22

Neutral
Select Comfort downgraded to Neutral from Outperform at Wedbush
As previously reported, Wedbush downgraded Select Comfort to Neutral from Outperform and lowered its price target to $22 from $25. Analyst Seth Basham believes the company will have difficulty meeting near-term expectations due to intense promotional activity in recent weeks, combined with recent store checks, lead him to believe Q4 is tracking below expectations.
10/20/16
BOFA
10/20/16
DOWNGRADE
Target $16
BOFA
Underperform
Select Comfort downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded Select Comfort to Underperform with a $16 price target following hte Q3 miss which included lower than expected comps and a cut in guidance. The firm believes increased consumer volatility from the election will make it difficult to win back lost sales, organic sales growth could be pressured by a peak in average ticket prices, and inconsistent results warrant a discounted multiple.
09/29/16
UBSW
09/29/16
INITIATION
Target $20
UBSW
Sell
Select Comfort initiated with a Sell at UBS
UBS analyst Michael Lasser started Select Comfort with a Sell rating and $20 price target. The analyst highlights as risks increasing competition and the company's reliance on existing customers. He recommends a "guarded" view of the mattress sector saying online-only players will grab "meaningful share" over the near-term. Lasser this morning also initiated shares of Tempur Sealy (TPX) with a Neutral rating.
12/06/16
WEDB
12/06/16
DOWNGRADE
WEDB
Neutral
Select Comfort downgraded to Neutral from Outperform at Wedbush

TODAY'S FREE FLY STORIES

21:00
05/26/17
05/26
21:00
05/26/17
21:00
General news
Breaking General news story  »

San Francisco Federal…

20:00
05/26/17
05/26
20:00
05/26/17
20:00
General news
Breaking General news story  »

San Francisco Federal…

JUNO

Juno Therapeutics

$23.30

-2.22 (-8.70%)

18:11
05/26/17
05/26
18:11
05/26/17
18:11
Hot Stocks
Juno Therapeutics director acquires 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

18:06
05/26/17
05/26
18:06
05/26/17
18:06
Hot Stocks
UnitedHealth's OptumHealth awarded $200.5M government contract »

UnitedHealth's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

VEC

Vectrus

$29.62

0.02 (0.07%)

17:56
05/26/17
05/26
17:56
05/26/17
17:56
Hot Stocks
Vectrus Systems awarded $212.03M modification to government contract »

Vectrus Systems was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMY

Imprimis

$3.34

-0.06 (-1.76%)

17:52
05/26/17
05/26
17:52
05/26/17
17:52
Syndicate
Breaking Syndicate news story on Imprimis »

Imprimis files $75M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRCP

IRSA Propiedades Comerciales

$43.58

-0.33 (-0.75%)

17:51
05/26/17
05/26
17:51
05/26/17
17:51
Syndicate
Breaking Syndicate news story on IRSA Propiedades Comerciales »

IRSA Propiedades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSKE

Daseke

$9.79

-0.11 (-1.11%)

17:44
05/26/17
05/26
17:44
05/26/17
17:44
Syndicate
Breaking Syndicate news story on Daseke »

Daseke files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECYT

Endocyte

$2.47

0.02 (0.82%)

, RNN

Rexahn

$4.04

0.09 (2.28%)

17:35
05/26/17
05/26
17:35
05/26/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Endocyte (ECYT),…

ECYT

Endocyte

$2.47

0.02 (0.82%)

RNN

Rexahn

$4.04

0.09 (2.28%)

TGTX

TG Therapeutics

$12.05

0.15 (1.26%)

SGMO

Sangamo

$7.25

-0.55 (-7.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 22

    Jun

ECYT

Endocyte

$2.47

0.02 (0.82%)

17:33
05/26/17
05/26
17:33
05/26/17
17:33
Hot Stocks
Endocyte to announce updated data on EC1456, EC1169 at ASCO »

Endocyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

PEP

PepsiCo

$117.91

0.38 (0.32%)

17:30
05/26/17
05/26
17:30
05/26/17
17:30
Periodicals
PepsiCo in talks to acquire Vita Coco owner All Market, Reuters reports »

PepsiCo is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCOV

Brightcove

$6.25

0.25 (4.17%)

17:25
05/26/17
05/26
17:25
05/26/17
17:25
Hot Stocks
Breaking Hot Stocks news story on Brightcove »

ESW Capital reports 8.08%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

SHIP

Seanergy Marine

$0.69

0.001244 (0.18%)

17:19
05/26/17
05/26
17:19
05/26/17
17:19
Hot Stocks
Seanergy Marine receives Nasdaq notice »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.93

0.07 (0.64%)

, DB

Deutsche Bank

$18.46

-0.39 (-2.07%)

17:10
05/26/17
05/26
17:10
05/26/17
17:10
General news
S&P advances to end week at record as Fed signals no rush to normalize policy »

The S&P 500 (SPX)…

F

Ford

$10.93

0.07 (0.64%)

DB

Deutsche Bank

$18.46

-0.39 (-2.07%)

BBY

Best Buy

$58.97

-2.28 (-3.72%)

HPQ

HP Inc.

$18.47

0.1 (0.54%)

BX

Blackstone

$32.58

0.11 (0.34%)

NOK

Nokia

$6.38

-0.02 (-0.31%)

AAPL

Apple

$153.61

-0.26 (-0.17%)

GM

General Motors

$33.07

0.47 (1.44%)

HUN

Huntsman

$24.75

-0.11 (-0.44%)

BF.A

Brown-Forman, also tag with BFA, BFB

$52.49

-0.21 (-0.40%)

BF.B

Brown-Forman, also tag with BFA, BFB

$51.73

0.13 (0.25%)

STZ

Constellation Brands

$180.93

0.79 (0.44%)

LOW

Lowe's

$80.91

-0.42 (-0.52%)

TIF

Tiffany

$86.18

0.36 (0.42%)

SHLD

Sears

$7.78

-0.7 (-8.25%)

SIG

Signet Jewelers

$49.31

-0.99 (-1.97%)

COST

Costco

$177.86

3.13 (1.79%)

ANF

Abercrombie & Fitch

$13.22

-0.83 (-5.91%)

AEO

American Eagle

$11.50

0.08 (0.70%)

EXPR

Express

$7.85

0.03 (0.38%)

TTWO

Take-Two

$77.07

-1.46 (-1.86%)

AZO

AutoZone

$615.62

8.28 (1.36%)

DSW

DSW

$16.73

-0.06 (-0.36%)

INTU

Intuit

$138.56

0.2 (0.14%)

PBYI

Puma Biotechnology

$79.75

1.7 (2.18%)

CHS

Chico's

$9.37

-0.39 (-4.00%)

SPLS

Staples

$8.98

-0.08 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 31

    May

  • 31

    May

  • 01

    Jun

  • 01

    Jun

  • 01

    Jun

  • 02

    Jun

  • 06

    Jun

  • 06

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 20

    Jun

  • 28

    Jun

  • 21

    Jul

BGNE

BeiGene

$37.42

-0.04 (-0.11%)

17:07
05/26/17
05/26
17:07
05/26/17
17:07
Syndicate
Breaking Syndicate news story on BeiGene »

BeiGene files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 06

    Jun

CGI

Celadon Group

17:06
05/26/17
05/26
17:06
05/26/17
17:06
Hot Stocks
Breaking Hot Stocks news story on Celadon Group »

Litespeed Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRD

Crawford & Company Inc.

, CRDA

Crawford & Co.

$7.65

0.01 (0.13%)

17:05
05/26/17
05/26
17:05
05/26/17
17:05
Hot Stocks
Crawford & Company COO Robinson to leave company »

Crawford & Company…

CRD

Crawford & Company Inc.

CRDA

Crawford & Co.

$7.65

0.01 (0.13%)

CRDB

Crawford & Company

$9.08

-0.02 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEAS

SeaWorld

$18.08

-0.13 (-0.71%)

17:03
05/26/17
05/26
17:03
05/26/17
17:03
Hot Stocks
Breaking Hot Stocks news story on SeaWorld »

Hill Path Capital raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMRC

Digimarc

$36.10

2.45 (7.28%)

17:03
05/26/17
05/26
17:03
05/26/17
17:03
Syndicate
Breaking Syndicate news story on Digimarc »

Digimarc files $100M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 06

    Sep

IPCI

Intellipharmaceutics

$1.94

-0.01 (-0.51%)

17:01
05/26/17
05/26
17:01
05/26/17
17:01
Syndicate
Breaking Syndicate news story on Intellipharmaceutics »

Intellipharmaceutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GWR

Genesee & Wyoming

$66.47

0.91 (1.39%)

16:57
05/26/17
05/26
16:57
05/26/17
16:57
Hot Stocks
Genesee & Wyoming CEO Hellmann named chairman of the board »

Genesee & Wyoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZG

Paramount Gold Nevada

$1.61

0.02 (1.26%)

16:54
05/26/17
05/26
16:54
05/26/17
16:54
Syndicate
Breaking Syndicate news story on Paramount Gold Nevada »

Paramount Gold Nevada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMO

Sangamo

$7.25

-0.55 (-7.05%)

16:53
05/26/17
05/26
16:53
05/26/17
16:53
Syndicate
Breaking Syndicate news story on Sangamo »

Sangamo files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

TGTX

TG Therapeutics

$12.05

0.15 (1.26%)

16:49
05/26/17
05/26
16:49
05/26/17
16:49
Syndicate
Breaking Syndicate news story on TG Therapeutics »

TG Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 22

    Jun

AVXL

Anavex

$5.88

-0.06 (-1.01%)

16:49
05/26/17
05/26
16:49
05/26/17
16:49
Syndicate
Breaking Syndicate news story on Anavex »

Anavex files to sell 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.